| Vi Oral Surgery, Inc | |
|
9149 Estate Thomas Suite # 201 St Thomas VI 00802-2615 | |
| (340) 777-5950 | |
| Not Available |
| Full Name | Vi Oral Surgery, Inc |
|---|---|
| Speciality | Dentist |
| Location | 9149 Estate Thomas, St Thomas, Virgin Island |
| Authorized Official Name and Position | Horace Griffith (OWNER) |
| Authorized Official Contact | 3407775950 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Vi Oral Surgery, Inc 9149 Estate Thomas Suite # 201 St Thomas VI 00802-2615 Ph: (340) 777-5950 | Vi Oral Surgery, Inc 9149 Estate Thomas Suite # 201 St Thomas VI 00802-2615 Ph: (340) 777-5950 |
| NPI Number | 1548412620 |
|---|---|
| Provider Enumeration Date | 10/21/2008 |
| Last Update Date | 10/21/2008 |
| Medicare PECOS PAC ID | 3173684701 |
|---|---|
| Medicare Enrollment ID | O20191016002848 |
News Archive
Medicare payment for end-stage renal disease care may soon be tied to performance and quality measures if a new proposed rule issued by the Centers for Medicare and Medicaid Services is finalized. "If the rule is finalized, ESRD providers that do not meet set standards" - two measures for anemia management and one for hemodialysis quality - "could have their Medicare payments lowered by up to 2 percent starting January 2012, the CMS said" (McKinney, 7/26).
The U.S. Food and Drug Administration today announced that drugs in the class of long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma in children or adults. Manufacturers will be required to include this warning in the product labels of these drugs, along with taking other steps to reduce the overall use of these medications.
Alimera Sciences, Inc. today announced that it priced its initial public offering of 6,550,000 shares of common stock at a price to the public of $11.00 per share on Wednesday, April 21, 2010.
For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.
Johnson and Johnson's experimental HIV drug rilpivirine or TMC278, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is being developed for use in combination therapy for treating the human immunodeficiency virus (HIV) that causes AIDS. Two clinical trials with the drug has shown that although its effectiveness was same as the existing anti-HIV drugs, its side effects were fewer. On the flip side nearly twice as many patients failed to respond to treatment with the new drug.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548412620 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223S0112X | Dentist - Oral And Maxillofacial Surgery | 1057 (Virgin Island) | Primary |
| Provider Name | Horace O Griffith |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1245348051 PECOS PAC ID: 1557378791 Enrollment ID: I20110121000579 |
News Archive
Medicare payment for end-stage renal disease care may soon be tied to performance and quality measures if a new proposed rule issued by the Centers for Medicare and Medicaid Services is finalized. "If the rule is finalized, ESRD providers that do not meet set standards" - two measures for anemia management and one for hemodialysis quality - "could have their Medicare payments lowered by up to 2 percent starting January 2012, the CMS said" (McKinney, 7/26).
The U.S. Food and Drug Administration today announced that drugs in the class of long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma in children or adults. Manufacturers will be required to include this warning in the product labels of these drugs, along with taking other steps to reduce the overall use of these medications.
Alimera Sciences, Inc. today announced that it priced its initial public offering of 6,550,000 shares of common stock at a price to the public of $11.00 per share on Wednesday, April 21, 2010.
For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.
Johnson and Johnson's experimental HIV drug rilpivirine or TMC278, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is being developed for use in combination therapy for treating the human immunodeficiency virus (HIV) that causes AIDS. Two clinical trials with the drug has shown that although its effectiveness was same as the existing anti-HIV drugs, its side effects were fewer. On the flip side nearly twice as many patients failed to respond to treatment with the new drug.
› Verified 7 days ago
News Archive
Medicare payment for end-stage renal disease care may soon be tied to performance and quality measures if a new proposed rule issued by the Centers for Medicare and Medicaid Services is finalized. "If the rule is finalized, ESRD providers that do not meet set standards" - two measures for anemia management and one for hemodialysis quality - "could have their Medicare payments lowered by up to 2 percent starting January 2012, the CMS said" (McKinney, 7/26).
The U.S. Food and Drug Administration today announced that drugs in the class of long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma in children or adults. Manufacturers will be required to include this warning in the product labels of these drugs, along with taking other steps to reduce the overall use of these medications.
Alimera Sciences, Inc. today announced that it priced its initial public offering of 6,550,000 shares of common stock at a price to the public of $11.00 per share on Wednesday, April 21, 2010.
For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.
Johnson and Johnson's experimental HIV drug rilpivirine or TMC278, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is being developed for use in combination therapy for treating the human immunodeficiency virus (HIV) that causes AIDS. Two clinical trials with the drug has shown that although its effectiveness was same as the existing anti-HIV drugs, its side effects were fewer. On the flip side nearly twice as many patients failed to respond to treatment with the new drug.
› Verified 7 days ago
Stuart Mark Wechter Dmd Pc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 5062 Fortets Gade, Ste 21, St Thomas, VI 00802 Phone: 340-774-1420 Fax: 340-715-1420 | |
Vi Cosmetic Dental Group, Llc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 9149 Estate Thomas Ste 201, St Thomas, VI 00802 Phone: 340-777-5950 Fax: 407-386-7222 | |
Connor Dental Center Dental Clinic Medicare: Medicare Enrolled Practice Location: 1916 Ninth St, St Thomas, VI 00802 Phone: 340-776-0030 Fax: 340-774-9760 | |
Vi Dental Center Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 9151 Estate Thomas Ste 203, St Thomas, VI 00802 Phone: 340-776-6056 Fax: 340-776-8161 | |
Happy Teeth Corporation Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 3004 Estate Altona, Suite 13, St Thomas, VI 00802 Phone: 340-776-4537 |